Results 1 to 10 of about 1,796 (202)

BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia. [PDF]

JCI Insight
MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood cancers and, in some patients, are the only ...
Booth CAG, Bouyssou JM, Togami K, Armand O, Rivas HG, Yan K, Rice S, Cheng S, Lachtara EM, Bourquin JP, Kentsis A, Rheinbay E, DeCaprio JA, Lane AA.   +13 more
europepmc   +4 more sources

Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

Journal of Scientific Research in Medical and Biological Sciences, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN.
Dwivedi, Dr sugreev Dwivedi Anuj
core   +3 more sources

Allogeneic Hematopoietic Cell Transplantation for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

Bone Marrow Transplantation, 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT).
Ahmed, Sairah, Al-Atrash, Gheath, Bashir, Qaiser, Champlin, Richard E, Hosing, Chitra, Kebriaei, Partow, Khouri, Issa F, Konopleva, Marina Y, Milton, Denái R, Nieto, Yago, Olson, Amanda L, Oran, Betul, Pemmaraju, Naveen, Popat, Uday R, Qazilbash, Muzaffar H, Rezvani, Katayoun, Rondon, Gabriela, Saini, Neeraj Y, Shpall, Elizabeth J, Srour, Samer A   +19 more
core   +4 more sources

Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]

Int J Mol Sci
: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens.
Galati D, Zanotta S, Florio F, Mele S, De Filippi R, Pinto A.   +5 more
europepmc   +3 more sources

Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis [PDF]

, 2022
open30siBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in men than in women, but the reasons for this sex bias are unknown.

core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy [PDF]

, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid neoplasm which shows a high rate of central nervous system (CNS) recurrence and overall survival (OS) of
Almeida, Julia, Alonso, Natalia, Bravo, Pilar, Caballero, María Dolores, Calvo, Carlota, Giménez, Teresa, González Barca, Eva, Heras, Cecilia, Martin Martin, Lourdes, Martínez, Violeta, Orfao, Alberto, Pomares, Hector, Pérez-Ceballos, Elena, Queizán, José-Antonio, Álvarez, Rodolfo   +14 more
core   +1 more source

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement : a case report and review of the literature [PDF]

, 2021
Background: We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting. Case presentation: A 54-year-old Caucasian male was referred to the Haematology
Albiol, Nil, Martino, Rodrigo, Mozos, Anna, Novelli, S., Pratcorona, Marta, Sierra, Jordi   +5 more
core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources

Trafficking properties of plasmacytoid dendritic cells in health and disease. [PDF]

, 2010
Plasmacytoid dendritic cells (PDCs) represent a subset of circulating leukocytes characterized by the ability to release high levels of type I interferon (IFN). Under homeostatic conditions PDCs are confined to primary and secondary lymphoid organs. This
Del Prete A, Facchetti F., Sozzani S, Vermi W   +3 more
core   +1 more source

Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm [PDF]

, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematopoietic malignancy characterized by dismal prognosis and overall poor therapeutic response. Since the biology of BPDCN is barely understood, our study aims to shed light on the genetic
Anagnostopoulos, Ioannis, Andrulis, Mindaugas, Endris, Volker, Goerdt, Sergij, Hartschuh, Wolfgang, Jöhrens, Korinna, Klapper, Wolfram, Klauschen, Frederick, Koch, Philipp-Sebastian, Lennerz, Jochen K., Pfarr, Nicole, Schulz, Miriam, Siebolts, Udo, Stenzinger, Albrecht, Weichert, Wilko, Wickenhauser, Claudia, Wolf, Thomas   +16 more
core   +1 more source